Product Name: CJC-1295 + Ipamorelin

Type: Growth Hormone Secretagogue Research Blend

Compound Composition:

• CJC-1295 – 5 mg
• Ipamorelin – 5 mg

Research Focus:

This blend combines CJC-1295 (no DAC), a modified growth hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue (GHS)[1][2]. CJC-1295 (no DAC) produces sustained, dose-dependent GH and IGF-1 increases[1], while Ipamorelin selectively stimulates GH release without raising ACTH or cortisol[3]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Research Interest:

- Growth hormone secretion studies

- Muscle growth and recovery signaling models

- Fat metabolism and body composition research

- Sleep and circadian rhythm pathway studies

Scientific Interest:

- Growth hormone axis regulation

- Anabolic and recovery signaling networks

- Endocrine system modulation

Reconstitution:

• Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total concentration (1.67 mg/mL each peptide).

• Typical daily range: 100–300 mcg of each peptide once daily (gradual titration).

• Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 33.3 mcg of each peptide on a U-100 insulin syringe.

• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Cycle:

Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)

Frequency: Inject once daily subcutaneously, typically before bed or upon waking[4]. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

IMPORTANT NOTICE:

This product is intended strictly for laboratory research. It is not intended to diagnose, treat, cure, or prevent any disease.